Moderna (NASDAQ:MRNA) Reaches New 12-Month Low – Time to Sell?

Moderna, Inc. (NASDAQ:MRNA) shares hit a new 52-week low on Monday . The company traded as low as $34.34 and last traded at $34.34, with a volume of 3466953 shares trading hands. The stock had previously closed at $42.25.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of recent analyst reports. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Sanford C. Bernstein initiated coverage on shares of Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target for the company. Bank of America reissued an “underperform” rating and issued a $41.00 price objective on shares of Moderna in a research note on Tuesday, December 10th. Barclays lowered their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a research note on Tuesday, November 26th. Four research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $78.83.

Moderna Stock Down 2.0 %

The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $13.26 billion, a price-to-earnings ratio of -5.92 and a beta of 1.60. The firm’s 50 day simple moving average is $41.78 and its 200-day simple moving average is $67.79.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna’s revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.39) EPS. On average, sell-side analysts anticipate that Moderna, Inc. will post -9.3 EPS for the current fiscal year.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 in the last ninety days. 15.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Moderna

Institutional investors and hedge funds have recently made changes to their positions in the business. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna in the 2nd quarter worth about $26,000. Plato Investment Management Ltd boosted its position in shares of Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after buying an additional 288 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new position in Moderna in the 2nd quarter valued at about $75,000. Blue Trust Inc. lifted its holdings in Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after purchasing an additional 574 shares in the last quarter. Finally, Larson Financial Group LLC lifted its holdings in Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.